We are pleased to announce that Cortalix has been awarded a grant from the Northern Netherlands Regional Development Agency (SNN) to support our project aimed at improving VHH-based ELISAs for prostate cancer.
Using our advanced VHH antibody discovery platform, we intend to develop highly specific single-domain antibodies capable of detecting subtle structural differences in PSA isoforms. This enables a new generation of diagnostic tests, e.g. ELISAs, that can more accurately distinguish between benign prostate enlargement and aggressive prostate cancer.
This innovation has the potential to reduce unnecessary medical procedures, improve clinical decision-making, and make prostate cancer diagnostics more efficient and patient-friendly.
We are grateful to SNN for supporting this important step forward in precision diagnostics.
This project is made possible with financial support from the European Union (EU), the European Regional Development Fund (EFRO) 2021-2017, co-funded through the SNN programme.
For more information about Cortalix: www.cortalix.com
Contact
For Cortalix:
Herman Steen, PhD
CEO Cortalix BV
info@cortalix.com
